ATOS
ATOSSA THERAPEUTICS, INC.Company Information
- Company Name
- ATOSSA THERAPEUTICS, INC.
- CIK
- CIK0001488039
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATOS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ATOS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-21
- Last sale
- 2023-11-15
- Shares purchased (TTM)
- 21,239
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,490,796
- Shares outstanding
- 8,908,511
- Ownership
- 16.73%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 9.32%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 32 | 41 | 52 | 58 | 65 | 71 | 75 | 80 | 84 | 88 | 94 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 31 | 37 | 46 | 56 | 63 | 69 | 74 | 77 | 82 | 87 | 92 | 98 | ||||||
| Other Assets Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | - | ||||||
| Equity Securities Without Readily Determinable Fair Value Amount | - | - | - | - | - | - | 0 | 0 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 32 | 38 | 48 | 58 | 65 | 71 | 76 | 79 | 86 | 91 | 96 | 102 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 3 | 4 | 4 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 3 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 5 | 7 | 8 | 8 | 7 | 5 | 5 | 6 | 6 | 5 | 5 | 3 | ||||||
| Employee Related Liabilities Current | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 0 | ||||||
| Liabilities | 5 | 7 | 8 | 8 | 7 | 5 | 5 | 6 | 6 | 5 | 5 | 3 | ||||||
| Preferred Stock Value | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 2 | 2 | 2 | 23 | 23 | 23 | 2 | 23 | 23 | 23 | 23 | 23 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 27 | 30 | 39 | 50 | 58 | 65 | 71 | 74 | 80 | 86 | 91 | 98 | ||||||
| Additional Paid In Capital Common Stock | - | - | - | - | - | - | - | - | - | - | - | 255 | ||||||
| Additional Paid In Capital | 291 | 287 | 286 | 263 | 263 | 262 | 283 | 258 | 257 | 257 | 256 | - | ||||||
| Treasury Stock Common Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -265 | -256 | -247 | -236 | -227 | -219 | -212 | -205 | -198 | -192 | -186 | -179 | ||||||
| Liabilities And Stockholders Equity | 32 | 38 | 48 | 58 | 65 | 71 | 76 | 79 | 86 | 91 | 96 | 102 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 175 | 175 | 175 | 175 | ||||||
| Common Stock Shares Issued | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | ||||||
| Shares Outstanding | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialATOSSA THERAPEUTICS, INC. (ATOS) — SEC Financial Statements & Analysis
ATOSSA THERAPEUTICS, INC. (ATOS) is a pharmaceutical preparations company, incorporated in DE. ATOSSA THERAPEUTICS, INC. trades on Nasdaq as: ATOS. ATOSSA THERAPEUTICS, INC. (ATOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, ATOSSA THERAPEUTICS, INC. carries a market cap of $17.19M, a P/E ratio of -0.46x, a P/B ratio of 0.64x, an enterprise value of $-8.90M, and an EV/EBITDA multiple of 0.23x. On profitability, it posts a Return on Equity (ROE) of -89.23%, a Return on Assets (ROA) of -77.91%, and a Return on Invested Capital (ROIC) of -13676.31%. Per share, it reports EPS of $-4.23, diluted EPS of $-4.23, free cash flow per share of $-4.02, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 31.31% year-over-year and EPS growth of 27.09% year-over-year. On the balance sheet, it maintains a current ratio of 5.69x, a quick ratio of 5.36x, working capital of $25.56M, a debt-to-equity ratio of 0.20x, a debt ratio of 0.17, free cash flow of $-35.78M (TTM), and net debt of $-26.09M. Figures sourced from SEC EDGAR.
- Market Cap
- $17.19M
- P/E TTM
- -0.46x
- EPS TTM
- $-4.23
- P/B TTM
- 0.64x
- ROE TTM
- -89.23%
- ROA TTM
- -77.91%
- Debt To Equity
- 0.20x
- Free Cash Flow TTM
- $-35.78M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ATOSSA THERAPEUTICS, INC. in?
ATOSSA THERAPEUTICS, INC. (ATOS) operates in the Pharmaceutical Preparations industry.
What exchange does ATOS trade on?
ATOSSA THERAPEUTICS, INC. (ATOS) trades on the Nasdaq.
Where is ATOSSA THERAPEUTICS, INC. incorporated?
ATOSSA THERAPEUTICS, INC. is incorporated in DE.
When was ATOSSA THERAPEUTICS, INC. (ATOS)'s most recent SEC filing?
ATOSSA THERAPEUTICS, INC. (ATOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is ATOS's market cap?
ATOSSA THERAPEUTICS, INC. (ATOS) has a market capitalization of $17.19M as of 2026-06-30.
What is ATOS's EPS (earnings per share)?
ATOSSA THERAPEUTICS, INC. (ATOS)'s trailing twelve month EPS is $-4.23 as of 2026-06-30.
What is ATOS's ROE (return on equity)?
ATOSSA THERAPEUTICS, INC. (ATOS)'s trailing twelve month Return on Equity (ROE) is -89.23% as of 2026-06-30.
What is ATOS's ROA (return on assets)?
ATOSSA THERAPEUTICS, INC. (ATOS)'s trailing twelve month Return on Assets (ROA) is -77.91% as of 2026-06-30.
What is ATOS's ROIC (return on invested capital)?
ATOSSA THERAPEUTICS, INC. (ATOS)'s trailing twelve month Return on Invested Capital (ROIC) is -13676.31% as of 2026-06-30.
What is ATOS's EV/EBITDA?
ATOSSA THERAPEUTICS, INC. (ATOS)'s trailing twelve month EV/EBITDA is 0.23x as of 2026-06-30.